2. Academic Validation
  3. In vitro investigation of BK-218, a new oral and parenteral cephalosporin

In vitro investigation of BK-218, a new oral and parenteral cephalosporin

  • Antimicrob Agents Chemother. 1990 Feb;34(2):349-54. doi: 10.1128/AAC.34.2.349.
I Szabó 1,  J Barabás,  A Tar,  L Kiss,  M Filep,  T Schmidt,  K Marossy,  B Tóth-Martinez,  G Barabás,  F Hernádi
Affiliations

Affiliation

  • 1 Institute of Biology, University Medical School, Debrecen, Hungary.
PMID: 2109582 DOI: 10.1128/AAC.34.2.349
Abstract

The Antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the beta-lactamases that were investigated, although two Enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent.

Figures
Products